Access to highly effective long-acting RSV-monoclonal antibodies for children in LMICs-reducing global inequity
- PMID: 39067468
- DOI: 10.1016/S2214-109X(24)00258-4
Access to highly effective long-acting RSV-monoclonal antibodies for children in LMICs-reducing global inequity
Conflict of interest statement
MP, LG, and SM are employees of Medicines Patent Pool, which is funded by Unitaid, the Swiss Agency for Development and Cooperation, the French Ministry for Europe and Foreign Affairs, the German Agency for International Cooperation, and the Ministry of Foreign Affairs of Japan. HJZ reports grants from the Bill & Melinda Gates Foundation, the US National Institutes of Health, Pfizer, MSD, and Sanofi to their institution, outside this work; and serving on an advisory board for MSD and on the Data Safety and Monitoring Board for Moderna. NIM and JT have received support for attending meetings or travel from the ResViNET Foundation. All other authors declare no competing interests.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources